Showing results (161-170 of 900) with videos related to

Sort By:
Pageof 90
Cancer|September 2, 2005
Mature T-cell leukemiasFarhad Ravandi, Hagop Kantarjian, Dan Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2012
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term resultsVijaya Raj Bhatt, Hagop Kantarjian, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemiaHun Ju Lee, Naval Daver, Hagop M Kantarjian, et al.
Leukemia & Lymphoma|December 5, 2008
Potential role of sorafenib in the treatment of acute myeloid leukemiaShahram Mori, Jorge Cortes, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Progress in acute myeloid leukemiaTapan M Kadia, Farhad Ravandi, Susan O'Brien, et al.
Current Oncology Reports|June 7, 2012
Philadelphia-positive acute lymphoblastic leukemia: current treatment optionsTheresa Liu-Dumlao, Hagop Kantarjian, Deborah A Thomas, et al.
British Journal of Haematology|April 5, 2014
The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approachMariela Sivina, Robert J Kreitman, Evgeny Arons, et al.
American Journal of Clinical Pathology|February 16, 2010
Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic featuresNikolay D Dimov, L Jeffrey Medeiros, Farhad Ravandi, et al.
The Lancet. Haematology|October 24, 2022
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trialElias Jabbour, Nicholas J Short, Nitin Jain, et al.
Leukemia|July 16, 2026
Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvageRoberta S Azevedo, Elias Jabbour, Nitin Jain, et al.
Pageof 90